Viking Therapeutics, Inc. (VKTX)

NCM – Цена в реальном времени. Валюта: USD

31.32

-0.40 (-1.26%)

При закрытии: May 12, 2026, 4:00 PM EDT

05.05.2026

Viking Therapeutics: Market Betting On Big Upside Through 2030

Viking Therapeutics is making really solid pipeline progress and possesses a unique dual agonist approach in the fast-growing obesity drugs market. VKTX targets a 5–10% market share, leveraging global expansion and late-stage development to compete with incumbents Lilly and Novo Nordisk. Nothing is over just yet. Phase 3 for VK2735 Oral is set for late 2026, with initial commercial ramp expected in 2028 and potential $1.3B sales by 2030. A hockey stick inflection could pan out.

05.05.2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity.

01.05.2026

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

Buy the story, sell the news. That's a reasonable explanation for why Viking Therapeutics NASDAQ: VKTX fell over 3% the day the company delivered its Q1 2026 earnings report.

30.04.2026

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.

30.04.2026

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. remains a hold as competitive pressure mounts in the GLP-1 obesity/diabetes space, with its lead VK2735 candidate lagging larger peers. VKTX's Phase 3 VANQUISH studies are fully enrolled, but pivotal data are not expected (by me) until late 2027/early 2028, making near-term catalysts limited. The upcoming Q3 maintenance study readout is a potential wildcard; positive results could enable VKTX to raise additional capital and regain momentum.

30.04.2026

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

29.04.2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled -- -- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 -- -- VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26 -- -- IND Filed for Novel Amylin Agonist VK3019; Phase 1 Trial Initiation Expected 2Q26 -- -- Strong Quarter-End Cash Position of $603 Million -- SAN DIEGO, April 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline and other corporate developments.

Видео

No Data

There is no data to display

Пресс-релизы

05.05.2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

29.04.2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

26.03.2026

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.

11.02.2026

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26 Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full Enrollment VK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26 Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 Million SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2025, and provided an update on its clinical pipeline and other corporate developments.

Viking Therapeutics, Inc. (VKTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics: Market Betting On Big Upside Through 2030

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Viking Therapeutics: Market Betting On Big Upside Through 2030

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Search stocks

Viking Therapeutics, Inc. (VKTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics: Market Betting On Big Upside Through 2030

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Viking Therapeutics: Market Betting On Big Upside Through 2030

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update